MGMT and central nervous system cancer: They revealed that CpG combinations with four or more consecutive CpGs within CpGs 72–82, including combined CpGs 76–79 and CpGs 74–78 used in commercial kits, were equally effective in predicting the MGMT mRNA expression and survival of patients with temozolomide-treated high-grade glioma [7], consistent with our findings.